SCHEMBL20600679

SCHEMBL20600679

OB(O)c1cc2cccnc2cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
ALDH1A1 P00352 6/20 0.44
CASP1 P29466 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CASP7 P55210 1/20 0.44
NPC1 O15118 3/20 0.43
POLB P06746 2/20 0.43
RAB9A P51151 1/20 0.43
CASP6 P55212 1/20 0.41
HTT P42858 3/20 0.41
MAPT P10636 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
NR4A2 P43354 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954501 0.81 ALDH1A1 (0.50) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL5833750 0.79 NPC1 (0.54) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL31262543 0.77 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AHTTMAPT
SCHEMBL29953663 0.77 ALDH1A1 (0.50) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL25206741 0.77 PDGFRB (0.44) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL30995270 0.77 PDGFRB (0.70) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL15876598 0.77 PDGFRB (0.70) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL25911367 0.77 ALDH1A1 (0.53) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL12121731 0.77 ALDH1A1 (0.53) PDGFRBPDGFRAALDH1A1CASP1MEN1
SCHEMBL18660264 0.75 CA1 (0.45) CYP1A2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
CN-110809577-A Modulators of adenosine A2A receptor 雷沃医疗有限公司 2020-02-18 CN disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 PDGFRB 1638/4885PDGFRA 1133/4885ALDH1A1 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.